| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 11,566 | 11,213 | 9,167 | 7,349 |
| Cost of goods sold | 1,906 | 1,802 | 1,495 | 1,004 |
| Gross profit | 9,660 | 9,411 | 7,672 | 6,345 |
| Research and development | 5,176 | 3,923 | 3,296 | 4,219 |
| Sales and marketing | 6,839 | 7,163 | 6,734 | 6,138 |
| General and administrative | 6,659 | 5,657 | 4,971 | 4,727 |
| Loss from operations | -9,014 | -7,332 | -7,329 | -8,739 |
| Interest income | 170 | 134 | 74 | 158 |
| Interest expense | 1,460 | 1,423 | 1,209 | 1,142 |
| Change in fair value of sepa, warrant and revenue base redemption liabilities | -2,932 | -330 | -835 | 4,974 |
| Change in fair value of contingent earnout liability | -2,524 | -700 | 820 | -2,360 |
| Other expense, net | -94 | -40 | -251 | -13 |
| Loss before income taxes | -10,806 | -8,291 | -10,370 | -2,402 |
| Income tax benefit (expense) | 5 | -3 | 5 | -3 |
| Net loss | -10,811 | -8,288 | -10,375 | -2,399 |
| Series a preferred stock conversion inducement | 18,516 | - | - | - |
| Deemed dividend related to seriesa preferred stock conversion | 11,947 | - | - | - |
| Undeclared dividends on series a preferred stock | 0 | 714 | 712 | 803 |
| Net loss attributable to common stockholders | -41,274 | -9,002 | -11,087 | -3,202 |
| Net loss per common share, basic (in dollars per share) | -0.96 | -0.27 | -0.39 | -0.12 |
| Net loss per common share, diluted (in dollars per share) | -0.96 | -0.27 | -0.39 | -0.12 |
| Weighted average common shares outstanding, basic (in shares) | 43,057,632 | 32,899,297 | 28,527,453 | 26,501,597 |
| Weighted average common shares outstanding, diluted (in shares) | 43,057,632 | 32,899,297 | 28,527,453 | 26,501,597 |
TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. (TLSI)